Orphan Drugs: Understanding the Rare Disease Market and Its Dynamics (Woodhead Publishing Series in Biomedicine) - Image 1

£125.00

Elsevier Orphan Drugs: Understanding the Rare Disease Market and Its Dynamics (Woodhead Publishing Series in Biomedicine)

Name: Orphan Drugs: Understanding the Rare Disease Market and Its Dynamics (Woodhead Publishing Series in Biomedicine)
Brand: Elsevier
Price: 125.0 GBP
Availability: InStock

Allied Health Professions

This is the most expensive it has ever been. Walk away.

£125 today · previous high £125 · all-time low £110

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 85 days · 85 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 85 days • 2 price levels

Days at Price

Current Price

Price Analysis

Most common price: £110 (78 days, 91.8%)

Price range: £110 - £125

Price levels: 2 different prices over 85 days

Description

This authoritative and comprehensive book makes the reader familiar with the processes of bringing orphan drugs to the global market. There are between 5,000 and 7,000 rare diseases and the number of patients suffering from them is estimated to be more than 50 million in the US and Europe. Before the orphan drug legislation enacted in the US in 1983, there was a limited interest from industry to develop treatment for very small patient groups. One of the difficulties is, of course, that similar levels of investment are needed from a pharmaceutical company to bring a drug to the market for both small and large patient groups.The journey from application of an orphan drug designation to a reimbursed market- approved drug is long and many obstacles occur during the journey.After reading the book, readers will: Understand who the players/stakeholders are in the rare orphan disease field and their specific needs and concerns: patients and patient organizations, researchers and treating physicians within the field, industry, regulatory and reimbursement bodies* Understand the strong partnership between the different players and the various initiatives to improve and increase access to treatment for patients; minimizing the gap between numbers of known diseases, orphan designations, approved drugs and paid drugs.The book also provides short practical case stories from patients and researchers, as well as representatives from industry and authorities on the challenges they came across in developing orphan drugs or getting access to orphan drugs. A comprehensive overview of strategy, key activities and considerations of how to bring an orphan drug from concept to the market and make it available to patients A source of updated information, news and trends for those who are already active in this fast-evolving field Covers the global definitions and the criteria for getting an orphan drug designation in, for example, the US and Europe

Product Specifications

Brand: Elsevier
Format: hardcover
ASIN: 1907568093
Category: Books > Subjects > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Allied Health Professions
Domain: Amazon UK
Release Date: 31 January 2014
Listed Since: 30 June 2011

Barcode

No barcode data available

Elsevier Orphan Drugs: Understanding the Rare Disease Market and Its Dynamics (Woodhead Publishing Series in Biomedicine)

This is the most expensive it has ever been. Walk away.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Barcode

Similar Products You Might Like

Global New Drug Development: An Introduction (ULLA Series in Pharmaceutical Sciences)

Artificial Intelligence for Drug Product Lifecycle Applications

Regulatory Protection in the Pharmaceutical and Life Science Industries: Challenges, Opportunities and Ongoing Reform (Elgar Monographs in Intellectual Property Law)

Propelling Innovation in New Drugs: Recommendations & Considerations (Pharmacology-Research, Safety Testing and Regulation)

Drug Development & Rare Pediatric Diseases: Issues, Strategic Plan, & Voucher Program Assessment (Pharmacology-research, Safety Testing and Regulation)

Development and Evaluation of Drugs: From Laboratory through Licensure to Market

Essentials of Translational Pediatric Drug Development: From Past Needs to Future Opportunities

Overcoming Obstacles in Drug Discovery and Development: Surmounting the Insurmountable―Case Studies for Critical Thinking

Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy

Medical Writing in Drug Development: A Practical Guide for Pharmaceutical Research

Biosimilars and Interchangeable Biologics: Strategic Elements

The Thriving Biopharma Business: How to Unlock Value and Drive Success in Biotech and Pharma

Global Issues in Pharmaceutical Marketing

Applied Therapeutics: The Clinical Use of Drugs

Evergreening Patent Exclusivity in Pharmaceutical Products: Supplementary Protection Certificates, Orphan Drugs, Paediatric Extensions and ATMPs

Drugs: From Discovery to Approval

Boosting Pharmaceutical Innovation in the Post-TRIPS Era: Real-Life Lessons for the Developing World

Statistics In the Pharmaceutical Industry: 14 (Chapman & Hall/CRC Biostatistics Series)

Managing the Drug Discovery Process: Insights and advice for students, educators, and practitioners

Digital Therapeutics: Strategic, Scientific, Developmental, and Regulatory Aspects (Chapman & Hall/CRC Biostatistics Series)

Development of Therapeutic Agents Handbook: 8 (Pharmaceutical Development Series)

Social Aspects of Drug Discovery, Development and Commercialization

Innovation and Marketing in Pharma: Emerging Practices - Volume 20

Theory of Drug Development (Chapman & Hall/CRC Biostatistics Series)